Intravenous ribavirin and hyperammonemia in an immunocompromised patient infected with adenovirus

Pablo Bertrand, Albert Faro, Patricia Cantwell, Andres Tzakis

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Ribavirin is a synthetic guanosine analog with activity against DNA and RNA viruses. It was studied in human trials, and no marked adverse effect was reported beyond the potential for teratogenicity and reversible mild anemia. An 8-year-old girl received a multivisceral transplant and developed adenoviral pneumonia. She was treated with intravenous ribavirin and became hyperammonemic. Discontinuation of ribavirin led to a decrease in ammonia levels. This pattern was repeated when the drug was restarted and discontinued. We hypothesize that in a toxic environment the interaction of ribavirin with hepatocellular mitochondrial enzymes may lead to hyperammonemia.

Original languageEnglish (US)
Pages (from-to)1216-1220
Number of pages5
JournalPharmacotherapy
Volume20
Issue number10
DOIs
StatePublished - Jan 1 2000

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this